Pneumococcal IgG- 23 Serotypes PNEUM

Synonyms

Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum

Allscripts (AEHR) Order Name

Pneumococcal IgG Serotypes

Sunrise Clinical Manager (SCM) Order Name

Streptococcus pneumoniae IgG Antibody

Clinical Info

Assessing the IgG antibody response to active immunization with nonconjugated, 23-valent vaccines
Assessing the IgG antibody response to active immunization with conjugated 13-valent, 15-valent and 
20-valent pneumococcal vaccines
Determining the ability of an individual to produce an antibody response to polysaccharide antigens, as 
part of an evaluation for humoral or combined immunodeficiencies

Specimen Type

Blood

Container

Gold Top Tube

Collection Instructions

Container/Tube: Gold Top Tube
Volume: 0.5 mL (0.4 mL min)
Transport Temperature: Refrigerated

Transport Instructions

Refrigerated

Specimen Stability

21 Days Refrigerated or Frozen

Methodology

Bead-Based Multiplex Immunoassay

Days Performed

Monday through Friday

Performing Laboratory

Mayo Medical Laboratories

CPT

86317 x 23

PDM

5905600

Result Interpretation

Results are reported in mcg/mL. 

  Effective : August 3, 2023

Serotype

Normal value

1 (1)

 > or =1.0

2 (2)

 > or =1.0

3 (3)

 > or =1.0

4 (4)

 > or =1.0

5 (5)

 > or =1.0

8 (8)

 > or =1.0

9N (9)

 > or =1.0

12F (12)

 > or =1.0

14 (14)

 > or =1.0

17F (17)

 > or =1.0

19F (19)

 > or =1.0

20 (20)

 > or =1.0

22F (22)

 > or =1.0

23F (23)

 > or =1.0

6B (26)

 > or =1.0

10A (34)

 > or =1.0

11A (43)

 > or =1.0

7F (51)

 > or =1.0

15B (54)

 > or =1.0

18C (56)

 > or =1.0

19A (57)

 > or =1.0

9V (68)

 > or =1.0

33F (70)

 > or =1.0
INTERPRETATION 
 

As a general guideline, nonimmunocompromised adults develop IgG antibodies approximately 4 to 6 weeks following nonconjugated vaccination.

 

Either of the following conditions is consistent with a normal response to Streptococcus pneumonia vaccination:

1. When comparing pre- and post-vaccination samples, antibody concentrations increased by at least 2-fold for

a. >50% of serotypes in children <6 years of age

b. >70% of serotypes for individuals >6 years of age

 

2. In either a pre- or post-vaccination sample, antibody concentrations >/= 1.0 mcg/mL for

a. >50% of serotypes for children <6 years of age

b. >70% of serotypes for individuals >6 years of age

Forms

edit